Long Term Medical Treatment of Congenital Hyperinsulinemic Hypoglycemia
Journal Title: Journal of Endocrinology and Diabetes - Year 2014, Vol 1, Issue 1
Abstract
Background: Hyperinsulinism is the most common cause of recurrent hypoglycemia in early infancy. Surgical treatment with partial/near total pancreatectomy has been the mainstay of treatment but does not result in complete remission of hypoglycemia and is associated with high risk of diabetes mellitus Design and methods: We retrospectively reviewed 23 patients (1979-2009) with congenital hyperinsulinism treated medically and surgically. Patients are divided in three groups: 1) treated with diazoxide 2) treated with octreotide alone or along with diazoxide 3) treated with surgical resection. Main outcomes measured are prevention of hypoglycemia, treatment side effects, onset of diabetes mellitus and effects on growth. Results: Eight patients were treated with diazoxide, 10 with octreotide alone or along with diazoxide and 5 had surgical resection. Four patients came off diazoxide between 5.5-10.5 years age, 3 are less than 5 years and still on treatment. Two patients came off octreotide at 5.5 and 7 years and six remain on treatment with their ages between 6 months and 12 years. No patient could come off medical treatment after surgical resection. 2 patients had diabetes in surgical group and none in medical group. Conclusion: Medical therapy with diazoxide, octreotide, glucagon and extensive feeding plan is an effective treatment for control of hypoglycemia in congenital hyperinsulinism patients.
Authors and Affiliations
Noman Ahmad, Mohamad Sharkia, Laura Stewart
Keywords
Related Articles
- EP ID EP332933
- DOI 10.15226/2374-6890/1/1/00106
- Views 163
- Downloads 0
Dyslipidemia in Subclinical Hypothyroidism: A Case-Control Study
Subclinical hypothyroidism (SCH) affects 7.5-8.5% of women and 2.8-4.4% of men. Overt hypothyroidism is characterized by dyslipidemia, however controversy persists regarding the lipids level in SCH and its clinical signi...
No Effect of Aprotinin (Trasylol™) on Degradation of Exogenous and Endogenous Glucagon in Human, Mouse and Rat Plasma
Traditionally, aprotinin (Trasylol™) has been added to plasma samples prior to glucagon analysis. However, the evidence for the need of aprotinin is sparse and based on results obtained when radioimmunoassay (RIA) techni...
Thyroid-Induced Toxicity of Check-Point Inhibitors Immunotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer
Immunotherapy represents a new strategy in the fight against cancer diseases based on the key role that immune system plays to identify and destroy foreign or abnormal cells in the body, including tumor cells. Nowadays,...
A New Diagnosis of Addison's Disease with a Twist
Addison's disease is a rare autoimmune endocrine disorder. It affects the cortex of the adrenal glands causing cortisol, aldosterone and adrenal androgen deficiencies. Addison's disease usually presents with non specific...
Pentraxin 3 as A Cardiovascular Marker in Primary Hyperparathyroidism
Aim: Pentraxin 3 (PTX3) is an acute-phase glycoprotein, which is increased in patients with cardiovascular disease (CVD) and considered as a predictor of CVD in the general population. Accumulating evidence suggests that...